Zealand Pharma A/S/ADR
ZLDPFNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ZLDPF. That does not mean none is planned.
Get an email about ZLDPF's next catalysts
Track Zealand Pharma A/S/ADR (ZLDPF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
GlucaGen
Hypoglycemia
Glepaglutide
Short Bowel Syndrome
Nicotine
Smoking Cessation
Thiotepa
Acute Lymphoblastic Leukaemia
dasiglucagon
Congenital Hyperinsulinism
Petrelintide
Overweight
ZP4207 (dasiglucagon)
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
Nicotine | Phase 3 | Smoking Cessation | - | - |
Thiotepa | Phase 3 | Acute Lymphoblastic Leukaemia | - | - |
dasiglucagon | Phase 3 | Congenital Hyperinsulinism | - | - |
Petrelintide | Phase 2 | Overweight | - | - |
ZP4207 (dasiglucagon) | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Frequently asked questions
What is in Zealand Pharma A/S/ADR's drug pipeline?β
CatalystAlert tracks 7 drug candidates in Zealand Pharma A/S/ADR's (ZLDPF) pipeline across Phase 3, Phase 2. Its lead program is dasiglucagon (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zealand Pharma A/S/ADR's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Zealand Pharma A/S/ADR (ZLDPF) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ZLDPF biotech catalysts?β
Add ZLDPF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zealand Pharma A/S/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
